While association between high PD-L1 expression and response to anti-PD-1/anti-PD-L1 treatment and overall survival has been published for both NSCLC and other malignancies, other studies have shown efficacy of the same antibodies to be independent of PD-L1 expression8. Here, CD274 is linked to non-small cell lung carcinoma.